SCHEMBL2731065

SCHEMBL2731065

COC(=O)C1CCCNC(=O)C1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
KMT2A Q03164 2/20 0.38
CCR2 P41597 1/20 0.37
CHRNB2 P17787 2/20 0.37
CHRNA4 P43681 2/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA7 P36544 1/20 0.37
TP53 P04637 1/20 0.34
OR51E2 Q9H255 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
POLB P06746 1/20 0.33
F2 P00734 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2153275 0.89 BRD4 (0.43) BRD4KMT2ACHRNB2CHRNA4CHRNB4
SCHEMBL15565329 0.83 KMT2A (0.36) SMN1; SMN2KMT2ACCR2OR51E2L3MBTL1
SCHEMBL1198241 0.80 KMT2A (0.41) SMN1; SMN2KMT2ACCR2OR51E2L3MBTL1
SCHEMBL22279768 0.78 BRD4 (0.46) BRD4KMT2ACHRNB2CHRNA4CHRNB4
SCHEMBL1026647 0.78 BRD4 (0.46) BRD4KMT2ACHRNB2CHRNA4CHRNB4
SCHEMBL28009406 0.78 BRD4 (0.46) BRD4KMT2ACHRNB2CHRNA4CHRNB4
Acetic Acid Methyl Ester SCHEMBL9151328 0.74 BRD4 (0.42) BRD4KMT2ACHRNB2CHRNA4CHRNB4
SCHEMBL11416871 0.74 BRD4 (0.48) BRD4KMT2ACHRNB2CHRNA4CHRNB4
SCHEMBL13406368 0.74 SMN1; SMN2 (0.50) SMN1; SMN2KMT2ACHRNB2CHRNA4CHRNB4
SCHEMBL3577499 0.73 THRB (0.53) BRD4SMN1; SMN2KMT2ACHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2632900-A2 CAPROLACTAM MGLUR5 RECEPTOR MODULATORS Merck Sharp & Dohme Corp. (US) 2013-09-04 EP disclosed
US-20130203735-A1 CAPROLACTAM MGLUR5 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. 2013-08-08 US disclosed
US-20130203735-A1 CAPROLACTAM MGLUR5 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. 2013-08-08 US disclosed
WO-2012058128-A2 CAPROLACTAM MGLUR5 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-05-03 WO disclosed
WO-2012058128-A2 CAPROLACTAM MGLUR5 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203735-A1 CAPROLACTAM MGLUR5 RECEPTOR MODULATORS GRM5, GRIK5, GRM1 BRD4 1177/4885SMN1; SMN2 2206/4885KMT2A 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.